H2020Индивидуална стипендия2016–2018

InnateMSDyn · Combining in vivo spectral biphoton imaging and multiparametric cytometry to characterize the dynamics of the innate immune response in a multiple sclerosis mouse model

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2016-07-01 → 2018-06-30
Финансиране от ЕС: 173 076 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Динамиката на имунните клетки и увреждането на нервните влакна при мишки с разсеяна склероза се анализират чрез специално изображение и цитометрия. Това помага да се разбере ролята на протеина VEGF и как той може да подобри качеството на живот на пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Combining in vivo spectral biphoton imaging and multiparametric cytometry to characterize the dynamics of the innate immune response in a multiple sclerosis mouse model

Multiple sclerosis is a disease affecting more than 2.3 million people worldwide. Combining the use of “multicolor” mice and advanced imaging techniques, my aim was to characterize the dynamics and the diversity of immune cells in a mice model of multiple sclerosis as well as axonal degeneration. We correlated the data with evolution of motor deficits. We showed that innate immune cells are of first importance in the spinal cord pathogenesis, with a complex recruitment and activation pattern. Finally, we treated the mice with anti-VEGF antibody to better understand the role of VEGF in this pathology and evaluate its potential as therapeutic drugs. The treatment allowed the mice to better recover after disease peak, leading to the idea that it could be helpful to improve patients’ quality of life.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Multiple sclerosis (MS) disease is dependent on an intricate interplay between the adaptive and innate immune systems. Nevertheless, none of the Food and Drug Administration-approved drugs target innate immune cells, because of their unclear roles in the disease process. However, innate immune cells implication in the MS disease is no longer put in doubt.The mobilization, differentiation and spatial-temporal distribution of brain resident and recruited peripheral innate immune cells, in relation with clinical scores, will be analyzed, as an alternative source of disease biomarkers and therapeutic targets.The project combines recent advances in (a) generation of multicolor transgenic reporter mice with subpopulations of cells expressing distinct fluorophores, (b) spectral bi-photon imaging to visualize the cells of interest directly in the spinal cord in living animals, at a subcellular resolution in real time, and (c) multiparametric flow cytometry to characterize over time inflammatory cell types in the spinal cord tissue after disease induction. The activated cells converging to the neuronal lesions, as well as the delay and the effect on the neurons, will be characterized. VEGF will also be tested as potential therapeutic drug, based on the known VEGF effects on neurons and immune cells. This data will provide new insights on MS disease setting up and implicated cells, correlated with clinical scores, neuronal damages and disease progression.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITE D'AIX MARSEILLE · MarseilleКоординаторФранция